Correlation Engine 2.0
Clear Search sequence regions

Fibrosis is a normal process for repairing injured tissue. However, aberrant or hyperfibrotic responses result in serious pathologic conditions and sometimes life-threatening diseases. A new class of drugs antagonizing type 1 lysophosphatidic acid receptor has been developed and is under investigation in clinical trials for the treatment of idiopathic pulmonary fibrosis and systemic fibrosis or scleroderma. This will be the first drug in its class to target G-protein-coupled receptors for lysophosphatidic acid.


Dong-Soon Im. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor. Archives of pharmacal research. 2012 Jun;35(6):945-8

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 22870802

View Full Text